Aug 20, 2026 | Blog
A clinical trial can reach its enrollment target and still produce evidence that is too narrow for the population it is intended to serve. The headline number may look reassuring, but it does not reveal whether the cohort reflects the relevant differences in age, sex,...
Aug 13, 2026 | Blog
A multi-country clinical trial can follow one protocol, test one investigational product, and pursue one scientific question, yet encounter different submission formats, review requirements, amendment procedures, and decision timelines in every participating country. ...
Aug 6, 2026 | Blog
A medicine may complete clinical trials with an acceptable safety profile and still reveal important risks only after thousands, or millions, of people begin using it. Approval is not the end of safety assessment. It is the point at which monitoring must expand from a...
Jul 30, 2026 | Blog
A video consultation can replace a clinic visit. It cannot replace clinical judgment, reliable connectivity, regulatory oversight, or accountable data governance. That distinction is often blurred in discussions about decentralized clinical trials (DCTs). Remote...
Jul 23, 2026 | Blog
The final participant visit is usually treated as the end of a clinical trial. For Africa’s health-product economy, it should be a handover point: the moment when evidence begins to inform regulatory approval, manufacturing, procurement and delivery. African...
Jul 17, 2026 | Blog
A clinical trial can leave behind a valuable dataset, a published paper and a team with new experience. It can also leave behind an empty office, expired service contracts, underused equipment and research professionals searching for the next grant. The difference is...
